Issue 142 • May 2024

Anticipation rises for RSV rollout as positive data emerges

Following major successes in the RSV landscape over the last few years, regulators debate rollout plans

Briefing

Genmab joins ADC arena with $1.8bn ProfoundBio acquisition

Feature

Molecular glues are the latest craze in pharma research, but what are they?

Comment

Lenmeldy becomes world’s most expensive drug

Interview

BARDA wants to back tech that can combat multiple infections, says director